Compare Two Stocks
Valuation, growth, earnings reaction and guidance credibility, side by sideLLYLilly (Eli)
FinDog View：Bullish
REGNRegeneron Pharmaceuticals
FinDog View：Neutral
| Metric | LLY | REGN |
|---|
| Close | 1,417.54 | 927.89 |
| Market Cap | $1.34T | $93.4B |
| 1M | +22.51% | +22.37% |
| P/E (TTM) | 50.2 | 19.5 |
| Forward P/E | 26.3 | 13.4 |
| P/E 5-Yr Percentile | 28 | 56 |
| P/S | 16.8 | 5.4 |
| P/B | 39.6 | 2.7 |
| Dividend Yield | 0.75% | 0.45% |
| Latest Quarter Revenue | $24.4B | $5.1B |
| Revenue YoY | +38.6% | +36.3% |
| Gross Margin | 83.9% | — |
| Latest Quarter EPS | 7.22 | 18.45 |
| Avg Post-Earnings Move | ±3.5% | ±1.4% |
| EPS Beat Rate | — | — |
| Guidance Hit Rate | — | — |
| Shareholder Yield | 0.88% | 3.66% |
| 90-Day Net Insider Buying | −$16.0M | −$6.5M |
LLY · Revenue, Last 8 Quarters ($B)
REGN · Revenue, Last 8 Quarters ($B)
